Stay updated on MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a Phase 1b/​2 Study of MEDI4736 in Combination With Tremelimumab for participants with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:49:21.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying that participants must be 18 years or older with histological or cytological confirmation of metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma, among other criteria.
    Difference
    12%
    Check dated 2024-05-22T21:30:30.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:14:48.000Z thumbnail image

Stay in the know with updates to MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page.